Stock Track | TG Therapeutics Soars 7.61% on Strong 2025 Results and Optimistic 2026 Revenue Guidance

Stock Track01-14

TG Therapeutics' stock surged 7.61% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.

The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with BRIUMVI U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including BRIUMVI U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.

CEO Michael Weiss highlighted BRIUMVI's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of BRIUMVI.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108946268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108946268","market":"nz","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Soars 7.61% on Strong 2025 Results and Optimistic 2026 Revenue Guidance","media":"Stock Track","content":"<p>TG Therapeutics' stock surged 7.61% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.</p><p>The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with BRIUMVI U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including BRIUMVI U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.</p><p>CEO Michael Weiss highlighted BRIUMVI's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of BRIUMVI.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Soars 7.61% on Strong 2025 Results and Optimistic 2026 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Soars 7.61% on Strong 2025 Results and Optimistic 2026 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-14 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics' stock surged 7.61% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.</p><p>The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with BRIUMVI U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including BRIUMVI U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.</p><p>CEO Michael Weiss highlighted BRIUMVI's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of BRIUMVI.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1108946268","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108946268","pubTimestamp":1768380033,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics' stock surged 7.61% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"股票赛道|TG Therapeutics飙升7.61%，2025年业绩强劲，2026年营收指引乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics' stock surged 7.61% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with BRIUMVI U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including BRIUMVI U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.CEO Michael Weiss highlighted BRIUMVI's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of BRIUMVI.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108946268","isCrawlerRequest":true}